FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 741 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Cancer in My Community: The Role of Cancer Screening in Guatemala November 5, 2020 Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... February 27, 2020 What is De-escalation Treatment in Cancer Research? May 30, 2023 Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically... March 23, 2023 Load more HOT NEWS New on NCI’s Websites for December 2020 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab EMA Recommends Granting a Marketing Authorisation for Capmatinib
